Conclusions
-
Docetaxel
remains the standard as first-line chemotherapy in mCRPC
-
Cabazitaxel
20 mg/m2 post-docetaxel is supported by level 1 evidence (accepting the risk go
a reduced efficacy vs reduced toxicity)
-
AR-targeted
agents may clinically affect the efficacy of docetaxel while cabazitaxel seems to
retain its activity
- Retrospective data suggest an
optimal OS
in mCRPC patients treated with 3 life extending
therapies (docetaxel, cabazitaxel, AR therapy)
